
|Videos|September 1, 2017
- Non-Small Cell Lung Cancer
- Volume 1
- Issue 1
Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
Author(s)Lyudmila A. Bazhenova, MD
Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the factors to take into consideration when treating a patient with non-driver non–small cell lung cancer with bevacizumab (Avastin).
Advertisement
Articles in this issue
over 8 years ago
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLCover 8 years ago
Emerging Treatment Strategies in Nonsquamous NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
5






































